Norges Bank
APLS

Norges Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Norges Bank’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,198,444
Closed -$30.1M – 96
2025
Q4 		$30.1M Buy
+1,198,444
New +$28.1M ﹤0.01% 1164
2025
Q3 		– Sell
-2,367,224
Closed -$41M – 110
2025
Q2 		$41M Buy
2,367,224
+793,623
+50% +$14.7M 0.01% 1024
2025
Q1 		$34.4M Buy
1,573,601
+487,358
+45% +$13.5M ﹤0.01% 1083
2024
Q4 		$34.7M Buy
1,086,243
+18,573
+2% +$559K ﹤0.01% 1102
2024
Q3 		$30.8M Sell
1,067,670
-11,935
-1% -$442K ﹤0.01% 1138
2024
Q2 		$41.4M Buy
1,079,605
+71,685
+7% +$3.25M 0.01% 974
2024
Q1 		$59.2M Buy
1,007,920
+61,707
+7% +$3.93M 0.01% 857
2023
Q4 		$56.6M Sell
946,213
-105,980
-10% -$5.38M 0.01% 847
2023
Q3 		$40M Buy
1,052,193
+29,167
+3% +$1.28M 0.01% 940
2023
Q2 		$93.2M Buy
1,023,026
+91,516
+10% +$7.9M 0.02% 600
2023
Q1 		$61.4M Sell
931,510
-115,944
-11% -$6.69M 0.01% 742
2022
Q4 		$54.2M Buy
1,047,454
+74,480
+8% +$3.95M 0.01% 777
2022
Q3 		$66.5M Buy
972,974
+27,094
+3% +$1.6M 0.02% 656
2022
Q2 		$42.8M Buy
945,880
+130,915
+16% +$5.97M 0.01% 844
2022
Q1 		$41.4M Buy
814,965
+174,798
+27% +$7.72M 0.01% 987
2021
Q4 		$30.3M Buy
640,167
+129,989
+25% +$5.12M 0.01% 1225
2021
Q3 		$16.8M Buy
510,178
+68,317
+15% +$3.84M ﹤0.01% 1582
2021
Q2 		$27.9M Sell
441,861
-71,189
-14% -$3.67M 0.01% 1325
2021
Q1 		$22M Sell
513,050
-149,647
-23% -$7.08M 0.01% 1489
2020
Q4 		$37.9M Buy
662,697
+19,906
+3% +$842K 0.01% 1164
2020
Q3 		$19.4M Buy
642,791
+538,104
+514% +$16.1M 0.01% 1443
2020
Q2 		$3.42M Sell
104,687
-280,313
-73% -$9M ﹤0.01% 1909
2020
Q1 		$10.3M Buy
+385,000
New +$13.7M ﹤0.01% 1601
2018
Q2 		– Sell
-75,000
Closed -$1.66M – 2129
2018
Q1 		$1.66M Hold
75,000
– – ﹤0.01% 2017
2017
Q4 		$1.63M Buy
+75,000
New +$1.1M ﹤0.01% 2002

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank's APLS Position: Q1 2026 in Review

Norges Bank sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 1,198,444 shares — an estimated $30.1M sold.

Norges Bank first reported a position in APLS in Q4 2017 and held it in 25 quarters. The position peaked at $93.2M in Q2 2023. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Norges Bank reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Norges Bank sold 1,198,444 Apellis Pharmaceuticals shares in Q1 2026, an estimated $30.1M.
  • Norges Bank first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 25 quarters.
  • Norges Bank's Apellis Pharmaceuticals position peaked at $93.2M in Q2 2023.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.